A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
about
Roles of lipoprotein receptors in the entry of hepatitis C virusHost-Targeting Agents to Prevent and Cure Hepatitis C Virus InfectionAnimal models for the study of HCVNanostructures for the Inhibition of Viral InfectionsGenetic Diversity Underlying the Envelope Glycoproteins of Hepatitis C Virus: Structural and Functional Consequences and the Implications for Vaccine DesignImpact of lipids and lipoproteins on hepatitis C virus infection and virus neutralizationUsage of adenovirus expressing thymidine kinase mediated hepatocellular damage for enabling mouse liver repopulation with allogenic or xenogenic hepatocytesMouse Systems to Model Hepatitis C Virus Treatment and Associated ResistanceProteomic approaches to analyzing hepatitis C virus biologyA novel monoclonal anti-CD81 antibody produced by genetic immunization efficiently inhibits Hepatitis C virus cell-cell transmissionHepatitis C virus cell entry: a target for novel antiviral strategies to address limitations of direct acting antivirals.Different requirements for scavenger receptor class B type I in hepatitis C virus cell-free versus cell-to-cell transmissionNatural history, treatment and prevention of hepatitis C recurrence after liver transplantation: past, present and future.Post-liver transplant hepatitis C virus recurrence: an unresolved thorny problem.Successful anti-scavenger receptor class B type I (SR-BI) monoclonal antibody therapy in humanized mice after challenge with HCV variants with in vitro resistance to SR-BI-targeting agentsTemporal analysis of hepatitis C virus cell entry with occludin directed blocking antibodies.Griffithsin has antiviral activity against hepatitis C virusMonoclonal antibodies against extracellular domains of claudin-1 block hepatitis C virus infection in a mouse model.Clearance of persistent hepatitis C virus infection in humanized mice using a claudin-1-targeting monoclonal antibodyNovel human anti-claudin 1 mAbs inhibit hepatitis C virus infection and may synergize with anti-SRB1 mAb.One-Step Recovery of scFv Clones from High-Throughput Sequencing-Based Screening of Phage Display Libraries Challenged to Cells Expressing Native Claudin-1.Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus.A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I.Applying antibody-sensitive hypervariable region 1-deleted hepatitis C virus to the study of escape pathways of neutralizing human monoclonal antibody AR5A.Hepatitis C virus: virology and life cycleStudy of hepatitis C virus entry in genetically humanized miceEffect of scavenger receptor class B type I antagonist ITX5061 in patients with hepatitis C virus infection undergoing liver transplantation.New perspectives for preventing hepatitis C virus liver graft infection.Identification of a New Benzimidazole Derivative as an Antiviral against Hepatitis C VirusHypervariable region 1 deletion and required adaptive envelope mutations confer decreased dependency on scavenger receptor class B type I and low-density lipoprotein receptor for hepatitis C virusHow hepatitis C virus invades hepatocytes: the mystery of viral entryUnderstanding the hepatitis C virus life cycle paves the way for highly effective therapies.Human monoclonal antibodies as candidate therapeutics against emerging viruses and HIV-1.Synthetic anti-lipopolysaccharide peptides and hepatitis C virus infection.New insights in recurrent HCV infection after liver transplantationHepatitis C virus infection and related liver disease: the quest for the best animal modelLipoprotein receptors and lipid enzymes in hepatitis C virus entry and early steps of infection.A Diverse Panel of Hepatitis C Virus Glycoproteins for Use in Vaccine Research Reveals Extremes of Monoclonal Antibody Neutralization Resistance.Hepatitis C virus vaccine candidates inducing protective neutralizing antibodies.Role of hypervariable region 1 for the interplay of hepatitis C virus with entry factors and lipoproteins.
P2860
Q26777338-065C51DB-BCC3-4285-BFB4-CBD3928E4E11Q26779128-F13E35CA-2686-4DC0-8131-D6C37D2B5723Q26797836-74B34E0F-DCD4-4F28-A3FA-ED113C33ECE3Q26801513-D528DD5A-3CEE-48AC-8AE0-B999378C8F6CQ26801759-B3C1F952-EA7D-45EC-83E0-C943387AD12BQ26864485-817CCBC1-0692-4376-8947-AFE44A41E485Q27306083-D1C5364A-63FB-4CC7-B314-5F4940322FE8Q27469038-608739CB-F99F-4D46-9779-AA41F2A64D61Q28085146-9B5EAEBB-E0C0-409A-8954-F6E028A14E1BQ28488372-B2AA1DEC-3D4A-4439-9873-6996B505A21AQ30386551-1651EED7-947A-40B5-B337-F1340595D906Q30541733-03B6CD26-7249-4107-AA4E-13322021C8A6Q34093754-BE1FC6D5-58A1-486D-A910-1EF6BD7581D1Q34093760-22A7DBC0-69D4-4391-8217-86719AF7D7D8Q34416004-3E7C98C4-2C5A-4AF9-B881-D14E8A31F1BFQ34649662-6E67B274-78B4-4290-9EDC-FC344A58C530Q35363633-037AEB9C-78D2-4FA2-9EDF-8FDAC4BDFBB9Q35488854-63186794-CB5D-4328-AED1-5C2C018E1DECQ35602284-965393FD-9024-466D-AF19-BAA32CDAD17DQ35828072-B8B344D9-0CD1-4FE6-8D9B-1EBED4C3F37CQ35863983-EBD867EF-8C66-44AB-BBE9-4D90AEB9EA12Q36010861-636DBC7C-EB03-4D52-AF97-7DCE09159221Q36133495-479C925C-9B5A-4DA5-BCBA-58CB0A675ED2Q36288404-D837D69F-33DF-49DB-BCFE-D7568E19D6A5Q36756358-A9A96922-CCB2-452D-99EF-F541250C074CQ36839847-117EF8B8-898C-425D-A258-8A1F3E5A880CQ36990362-37B48260-DA9D-4D1D-B7D3-5911607BC1F9Q37015805-111904DF-AF84-4A92-B22E-CB2B5920C856Q37252935-26EC0940-001A-4FF6-A364-324070577F3BQ37547255-E09F5690-C066-447E-931B-4437D903D56CQ37682499-2AE3EDB2-7F62-4F2F-9F0E-12D0EA92576DQ37699395-61244499-2261-4A32-87D6-AE841D9186BCQ38098075-13C79448-0861-439F-BD0E-1B6FEE797F80Q38103293-30FD4B44-33CE-42C3-9C41-9C2F74EECFE6Q38109628-43E52525-20B3-42B6-9E5A-8B3DD4F85E80Q38125192-AE06CAC6-AE8F-44B3-847C-E32C46202DF3Q38166372-BA06A177-1D78-476D-837A-289B6ED4F2A1Q38809451-3A108DDE-DEB4-4B42-95FB-01544266EE8BQ38856649-24C08D60-BF4B-41B6-9744-9B788D57E397Q38964215-1B1179FF-9DD1-4BEF-9C75-537759C3F52E
P2860
A human monoclonal antibody targeting scavenger receptor class B type I precludes hepatitis C virus infection and viral spread in vitro and in vivo.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@ast
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@en
type
label
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@ast
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@en
prefLabel
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@ast
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@en
P2093
P2860
P50
P356
P1433
P1476
A human monoclonal antibody ta ...... l spread in vitro and in vivo.
@en
P2093
Alfredo Nicosia
Ali Farhoudi
Charles M Rice
Christopher T Jones
Isabelle Desombere
Katarzyna Grzyb
Lieven Verhoye
Riccardo Cortese
Timothy Sheahan
P2860
P304
P356
10.1002/HEP.24692
P407
P577
2011-12-16T00:00:00Z